Elanix Biotechnologies AG has entered into co-development agreement with Dermacon GmbH, a company engaged in production and marketing of user-friendly medical devices, to develop medical devices for its first cover wound care franchise. Under the terms of the agreement, Dermacon will apply its extensive expertise to design progenitor cell matrix-based products for Elanix Biotechnologies and guide the development and CE mark regulatory process. Elanix Biotechnologies will retain all commercial rights to any resulting products utilizing its progenitor cells. The wound management products to be developed under the agreement will incorporate progenitor cells or their derivatives into a product classified as a medical device. These devices enable the controlled release of the cells and their active functional proteins to create a healing environment that supports tissue regeneration and helps prevent infections. The partnership enables Elanix Biotechnologies and Dermacon to develop progenitor cell medical devices to accelerate wound healing.